Our study is the first to demonstrate PI3K‐C2α acts as a driver of EGFR inhibitor resistance in HNSCC, as reducing PIK3C2A transcript levels led to growth inhibition and increased sensitivity to the EGFR inhibitor gefitinib, especially in long‐term culture models. This evidence concerns the gene PIK3C2A and head and neck squamous cell carcinoma.